Company intelligence / Profile preview

Orphan Canada

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Orphan Canada was a specialty pharma company commercializing and distributing therapies for rare and genetic diseases in Canada. Flagship products included PHOTOFRIN (porfimer sodium) for certain cancers and ATryn (recombinant antithrombin) for hereditary antithrombin deficiency; both drugs were already approved and marketed in Canada at the time of acquisition.

Therapeutic areas: OncologyRare DiseasesHematology
Modalities: Small moleculeBiologicRecombinant protein
Industry: Biotech

Partnerships

Pinnacle Biologics (for PHOTOFRIN distribution, pre-acquisition)Bourne Partners (co-founders, corporate development)

Beyond the preview

Go deeper on Orphan Canada.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orphan Canada.

Explore the full profile